

OPEN PEER REVIEW REPORT 2

Name of journal: Neural Regeneration Research

Manuscript NO: NRR-D-22-00141

Title: Hematopoietic progenitor cells as diagnostic and therapeutic targets in Alzheimer's disease

Reviewer's Name: Rongcan Luo

Reviewer's country: China

COMMENTS TO AUTHORS

In this manuscript entitled "Hematopoietic progenitor cells as diagnostic and therapeutic targets in Alzheimer's disease", the authors reviewed the recent work and ongoing clinical trials testing the feasibility of Hematopoietic progenitor cells and endothelial progenitor cells as early biomarkers of AD and pharmacological targets in the future. Overall, this paper is interesting, and there are some minor points for improvement.

The following references should be cited

1. Michaud JP, Richard KL, Rivest S. Hematopoietic MyD88-adaptor protein acts as a natural defense mechanism for cognitive deficits in Alzheimer's disease. *Stem Cell Rev Rep.* 2012;8(3):898-904. doi: 10.1007/s12015-012-9356-9.
2. Naert G, Rivest S. Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. *Mol Med.* 2012;18(1):297-313. doi: 10.2119/molmed.2011.00306.
3. Shin JW, Lee JK, Lee JE, Min WK, Schuchman EH, Jin HK, Bae JS. Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1 α in an Alzheimer's disease mouse model. *Stem Cells.* 2011;29(7):1075-89. doi: 10.1002/stem.659.
4. Neri T, Bucciantini M, Rosti V, Raimondi S, Relini A, Massa M, Zuccotti M, Donadei S, Stefani M, Redi CA, Merlini G, Stoppini M, Garagna S, Bellotti V. Embryonic stem and haematopoietic progenitor cells resist to A β oligomer toxicity and maintain the differentiation potency in culture. *Amyloid.* 2010;17(3-4):137-45. doi: 10.3109/13506129.2010.530138.
5. Sanchez-Ramos J, Song S, Cao C, Arendash G. The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-review. *BMC Neurosci.* 2008;9 Suppl 2(Suppl 2):S3. doi: 10.1186/1471-2202-9-S2-S3.
6. Laske C, Stellos K, Eschweiler GW, Leyhe T, Gawaz M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? *J Alzheimers Dis.* 2008;15(1):83-95. doi: 10.3233/jad-2008-15107.
7. Arduino I, Iacobazzi RM, Riganti C, Lopodota AA, Perrone MG, Lopalco A, Cutrignelli A, Cantore M, Laquintana V, Franco M, Colabufo NA, Luurtsema G, Contino M, Denora N. Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease. *Int J Pharm.* 2020;591:120011. doi: 10.1016/j.ijpharm.2020.120011.